Trial Profile

Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enasidenib (Primary)
Indications Adenocarcinoma; Carcinoma; Chondrosarcoma; Multiple hamartoma syndrome; Neuroblastoma; Neuroendocrine carcinoma; Sinonasal-undifferentiated-carcinoma
Focus Therapeutic Use

Most Recent Events

17 Jan 2025 Planned number of patients changed from 25 to 40.
10 Jul 2024 According to an abstract published at 60th Annual Meeting of the American Society of Clinical Oncology ,the trial design was discussed along with Planned number of patients changed from 30 to 25.
05 Mar 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 6 Mar 2024 to 11 Mar 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com